Nuvation Bio
NUVB
203 hedge funds and large institutions have $818M invested in Nuvation Bio in 2025 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 83 increasing their positions, 48 reducing their positions, and 17 closing their positions.
129% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 17
97% more call options, than puts
Call options by funds: $7.64M | Put options by funds: $3.87M
86% more capital invested
Capital invested by funds: $439M → $818M (+$379M)
73% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 48
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
12% more funds holding
Funds holding: 182 → 203 (+21)
1.61% less ownership
Funds ownership: 66.04% → 64.43% (-1.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$8.4M |
| 2 |
Jane Street
New York
|
+$6.33M |
| 3 |
AC
Armistice Capital
New York
|
+$4.89M |
| 4 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$3.68M |
| 5 |
Two Sigma Investments
New York
|
+$3.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$13.8M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$9.01M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$8.8M |
| 4 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$6.03M |
| 5 |
BlackRock
New York
|
-$3.08M |
NUVB Hedge Fund Activity: Q3 2025 in Review
203 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q3 2025, worth a combined $818M — up 86% from $439M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new NUVB positions and 17 closed out — a net gain of 22 holders — while 83 added to existing stakes and 48 trimmed.
The largest buyer was Nuveen, adding an estimated $8.4M. The largest seller was Octagon Capital Advisors, cutting an estimated $13.8M.
- 203 institutional investors held Nuvation Bio (NUVB) as of Q3 2025, up from 182 in Q2 2025.
- Funds reported $818M of Nuvation Bio stock for Q3 2025, up 86% quarter-over-quarter.
- 39 funds opened new Nuvation Bio positions in Q3 2025 and 17 closed out, a net change of +22 holders.
- The largest Nuvation Bio buyer in Q3 2025 was Nuveen, an estimated $8.4M added.
- The largest Nuvation Bio seller in Q3 2025 was Octagon Capital Advisors, an estimated $13.8M sold.
Based on aggregated 13F filings for Q3 2025.